DESIGN AND INVITRO CHARACTERIZATION OF METFORMIN LOADED RESEALED ERYTHROCYTES by S, Aiswarya et al.
Vol 10, Issue 4, 2017
Online - 2455-3891 
Print - 0974-2441
DESIGN AND IN VITRO CHARACTERIZATION OF METFORMIN LOADED RESEALED 
ERYTHROCYTES
AISWARYA S, PARVATHY S, ANEESH TP*, VIDYA VISWANAD*
Amrita School of Pharmacy, Amrita University, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, India. Email: 
vidyaviswanad@aims.amrita.edu/aneeshtp@aims.amrita.edu
Received: 15 December 2016, Revised and Accepted: 16 January 2017
ABSTRACT
Objective: Metformin is an oral antidiabetic drug in the biguanide class. It is the first-line drug of choice for the treatment of type 2 diabetes. The 
objective of this study was to retard the release of metformin using carrier erythrocyte for getting a parenteral slow release depot formulation.
Methods: The study retards the release of metformin by encapsulating in carrier erythrocyte. Endocytosis is the method used for the encapsulation 
of the drug metformin.
Results: The optimized formulation shows 98.34% of drug release within 12 days. From the in vitro release data, zero order kinetic graph shows the 
best fit graph. % cell recovered was found to be 73-78% and it suggests that the loading technique was less destructive.
Conclusion: The optimized formulation is a perfect carrier for the parenteral slow release depot of metformin.
Keywords: Resealed erythrocytes, Cross-linking, Cell recovery, Endocytosis, Slow release depot formulation.
INTRODUCTION
Diabetes mellitus is an aggregation of metabolic illness with high 
blood glucose levels that result from defects clinched alongside insulin 
response secretion, alternately action, or both. It’s a disease that can 
be classified under the category of chronic systemic diseases (CSDs). 
CSD are diseases that affect the whole body or different part of the 
body [1]. CSD diabetes mellitus is an aggregation of metabolic illnesses 
portrayed eventually Tom’s perusing helter skelter blood glucose levels 
that result from defects clinched alongside insulin response secretion, 
alternately action, or both. Most often CSDs are treated with oral drugs. 
Some of the drugs used for these chronic diseases include drugs having 
relatively shorter half-life. Hence, a multiple dosage regimen is needed 
to maintain the therapeutic plasma level concentration which leads 
to toxicity due to the accumulation [2]. Biguanide drug metformin is 
used in the treatment of type 2 diabetes mellitus and polycystic ovary 
syndrome. It is available in market as oral tablet. Administration of 
the drug by oral route is often associated with several gastrointestinal 
problems. The bioavailability of the drug is also low due to poor 
intestinal permeability. Therefore increased the dosage of metformin 
is usually advised to the patients to obtain desired therapeutic 
concentration. Furthermore, the shorter half-life of the drug in systemic 
circulation increases the frequency of its administration [3]. Developing 
a parenteral controlled slow release formulation is, therefore, essential 
so that it can bypass the gastrointestinal side effects and reduces the 
frequency of administration of metformin. Incorporation of the drug in 
vesicular bodies is a usually adopted strategy for parenteral slow release 
formulation but it possesses a disadvantage of rapid clearance from 
circulation by Reticuloendothelial system (RES) [4]. So incorporating 
body’s own erythrocyte may avoid RES clearance. Erythrocytes are 
made of cell membrane which constitutes phospholipid bilayer like any 
novel vesicular bodies [5,6]. However, they are not recognized by the 
macrophage system because of variety of proteins residing on the red 
blood cell (RBC) membrane. After all, change in membrane structure 
occurs and these cells are taken up by RES and are destroyed. Then, 
either the drug is cleared by the system or it is further reached the 
systemic circulation by the process known as extravasation. Hence, the 
drug is continuously supplied for a prolonged basis [7]. Phospholipids in 
erythrocytes are found as bilayer with choline-containing phospholipid-
like phosphatidylcholine (PC) and sphingomyelin (SM) in the outer layer 
and amine containing phospholipid-like phosphatidylethanolamine and 
phosphatidylserine (PS) in the inner layer. Erythrocytes can be used as 
drug carrier for slow release depot formulation provided that there 
should not any exposure of PS during the loading procedure. Exposure 
of PS is preferred if we are supposed to target RES system because PS is 
a self-marker for macrophages. There are various methods for loading 
drug in erythrocytes. However, all the methods are not equally suitable 
for loading drugs to treat CSDs. The method we adopt should not cause 
any structural change during the treatment. This can be confirmed 
by viewing under an electron microscope. Any plasma membrane 
deformity occurs during the loading processes may cause it recognized 
by the macrophages, and they will be cleared off from the circulation. 
Endocytosis is used for loading metformin in erythrocyte as it is a less 
destructive method. Endocytosis occurs by engulfing the substance 
into the erythrocytes similar to phagocytosis [8]. Substance to be 
entrapped into the RBC should have a degree of water solvability and 
resistivity to a basement within the erythrocytes [9]. As endocytosis 
is a less destructive method, greater circulation half-life is achieved. 
Type 2 diabetes mellitus and polycystic ovary syndrome are chronic 
diseases requiring long-term therapy, the long circulation half-life 
and prolonged zero order release are usually preferable. When this 
condition is achieved, the dose and frequency of administration of 
metformin can be reduced. Delivering metformin loaded erythrocytes 
intravenously will probably reduce gastrointestinal side effects by 
bypassing the gastrointestinal route. Reduction in dosing frequency 
and controlled release of metformin will reduce the dose-related side 
effect like lactic acidosis. Hence, the object of our present study is to 
imbecile the release of metformin using carrier erythrocyte for getting 
a parenteral slow release depot formulation.
METHODS
Metformin which is obtained as gift sample from Yarrow Chem, Mumbai, 
adenosine triphosphate is from Loba Chemie Pvt. Ltd, Mumbai, Calcium 
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chloride is obtained from Nice Chemicals, Kochi. Moreover, all other 
chemicals used in this study are of analytical reagent grade.
Physical interaction of RBC with metformin
Fourier transform infrared (FTIR) spectra
FTIR spectra of metformin, RBC, and metformin-RBC are taken and 
studied for the interaction. Blood samples were lyophilized, and FTIR 
was taken.
In silico analysis
Docking studies were carried out using Auto dock 4.2 between 
human oxy hemoglobin chain A (PDB: 2DN1) and metformin after 
identification of the possible binding pocket using CASTp. AutoDock 
uses one of the several conformational search algorithms to explore 
the conformational states of a flexible ligand, using the maps generated 
by AutoGrid to evaluate the ligand-protein interaction at each point 
in the docking simulation. Here, in this study, metformin-human oxy 
hemoglobin interaction was studied.
Collection of erythrocytes
RBC was collected from the blood bank of Amrita Institute of Medical 
Sciences, Kochi. The institution has an informed consent form from 
donors that their blood can be used for biomedical research. RBC was 
washed with phosphate buffered saline (PBS) (pH 7.4) to remove the 
traces of heparin because it acts as an analytical interference during 
the study as the absorption maxima of heparin and metformin is 
232 nm. The supernatant buffer was removed by aspiration followed by 
centrifugation to get packed volume cell. Instead of distilled water for 
washing erythrocyte care was taken for using PBS 7.4 because distilled 
water is a perfect hemolysing agent.
Loading of metformin in RBC
For loading metformin into erythrocyte, concentrations having no or 
little hemolysis were selected. For that, a series of the concentration 
of metformin ranging from 1 to 10 mg/ml was prepared. The solutions 
were then added to RBC suspended in PBS and allowed to stand for 
an hour. The supernatant liquid was withdrawn, and % hemolysis 
was determined for each concentration of metformin. The percentage 
hemolysis was calculated using the formula.
% hemolysis=
Absorbance of sample  absorbance of blank
Abso

rbance of positive control
×100
The supernatant obtained by adding triton X to erythrocyte suspension 
was used as positive control. 1% v/v of triton X is a detergent with 100% 
hemolyzing capacity. The supernatant obtained when adding normal 
saline to the erythrocyte suspension was used as blank. The absorbance 
was ultraviolet (UV) spectrophotometrically determined at 540 nm. By 
determining the % hemolysis, we can optimize the concentration of 
metformin to be loaded to erythrocytes. Drug loading was done by the 
method of endocytosis and normal transportive mechanism.
Method of endocytosis
To 5 ml of buffer containing 2.5 mmol ATP, 1 mmol CaCl2.2H2O and 
2.5 mmol MgCl2, 1 ml of selected concentrations of metformin were 
added. To the solution, 0.65 ml of erythrocyte was added and incubated 
at 0°C for 15 minutes. Then, it was resealed using 0.9% sodium chloride 
solution at 37°C. The suspension then obtained was washed twice with 
cold PBS followed by centrifugation at 5000 rpm for 15 minutes [10]. 
The method of endocytosis versus normal transportive mechanism at 
our different mechanism was shown in Table 1.
Normal transportive mechanism
To 5 ml of PBS 7.4, 1 ml of selected concentrations of metformin was 
added. To the solution, 0.65 ml of erythrocyte was added and incubated 
at 0°C for 15 minutes. Then, it was resealed using 0.9% sodium chloride 
solution at 37°C. The suspension then obtained was washed twice with 
cold PBS followed by centrifugation at 5000 rpm for 15 minutes. The 
centrifugation was done to remove the metformin that was bound to 
the surface of RBC membrane [11].
Summary of 2*4 factorial ANOVA and post-hoc Tuckey HSD test was 
shown in Tables 2 and 3.
The loaded erythrocytes were further in vitro characterized for their 
suitability as slow release parenteral depot.
Characterization of metformin loaded resealed erythrocytes
The in vivo performance operation of resealed erythrocyte is affected 
to a great extent by their in vitro biological prop of erythrocytes. Hence, 
in vitro characterization f Mannikin an important part of the study 
involving the use of such cellular carriers.
Encapsulation efficiency
The encapsulation efficiency was calculated for erythrocytes loaded 
by endocytosis and was compared with drug loaded by normal 
transportive mechanism. In normal transportive mechanism, the drug 
loading was carried out in PBS alone. This method involves the loading of 
erythrocytes with drug without disrupting the erythrocyte membrane 
in by incubating the drug and erythrocytes. To determine encapsulation 
efficiency, the RBC membrane was deproteinized using methanol 
followed by centrifugation. 1 ml of the supernatant was pipetted out 
and drug content was determined using UV-visible spectrophotometer 





Table 1: Data table of endocytosis method versus normal transportive mechanism at four different concentrations
Method Concentration 1 mg Concentration 4 mg Concentration 7 mg Concentration 10 mg
Normal transportive mechanism 123.4 1595.20 4223.80 6988
Endocytosis  310.6 1898.4 2081.8 2046
Table 2: 2×4 factorial ANOVA table for the influence of method and concentrations
ANOVA summary
Source SS df MS F p
Method of loading (r) 19559436.87 1 19559436.87 4602.31 <0.0001
Concentration added (c) 66964180.83 3 22321393.61 5252.2 <0.0001
r × c 24132854.5 3 8044284.83 1892.81 <0.0001
Error 72248.56 17 4249.92
Total 110728720.76 24
ANOVA: Analysis of variance
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In vitro drug release
The drug release study for the concentration with highest loading 
efficiency was carried out for 12 days in an orbital shaking incubator 
at 37°C. 1 ml of the supernatant layer was withdrawn at various time 
intervals. It was then deproteinized using methanol and passed through 
0.22 µm syringe filter to remove the precipitated protein. The amount 
of metformin released at each time interval was estimated by UV 
spectrophotometry at 232 nm. To study the release kinetics, the data 
obtained from in vitro drug release studies were plotted in various 
kinetic models [12].
Effect of cross-linking agent on drug release
The loaded erythrocytes were treated with glutaraldehyde crosslinker. 
In vitro drug release was also taken for glutaraldehyde treated 
formulations to study the effect of concentration of cross-linking 
agent on drug release. The concentration of cross-linking agent was 
varied from 0.2-0.8% v/v and was treated to erythrocytes loaded with 
optimized concentration. Glutaraldehyde was used as cross-linking 
agent, as it makes more chemically and thermostable cross-links with 
protein than other aldehyde crosslinkers [13].
Hematological parameters, such as osmotic fragility test and turbulence 
shock, were studied and compared with normal erythrocytes.
Osmotic fragility test
Osmotic fragility test was carried out for both loaded and unloaded 
erythrocytes. For this, a series of concentration of sodium chloride 
ranging from 0.1% to 0.9% w/v was prepared. A drop of the loaded and 
unloaded erythrocytes was added separately to different concentrations 
of sodium chloride taken in test tube. Then, it was centrifuged and 
allowed to stand for 1 hr at 37°C. The supernatant was taken, and the 
absorbance was noted at 540 nm in a UV-visible spectrophotometer [14]. 
Osmotic fragility curve was then constructed by plotting concentration 
of sodium chloride in X axis and for both loaded and normal erythrocyte. 
Statistical analysis was applied to predict the significant difference 
between the loaded and normal erythrocytes.
Turbulence shock studies
Turbulence stupor enables an evaluation to be made of the stability of 
the loaded erythrocytes against the Sturm und Drang accent exerted 
by the cells against in-vivo circulation turbulence. The trial run is 
performed by the method of Deloach et al. whereby the erythrocyte 
suspension was passed through a 22-standard of measurement needle 
several times at a flow rate of 10 ml/minutes and % hemolysis was 
calculated. The number of passes was plotted against % hemolysis for 
both loaded and unloaded erythrocytes [15].
Cell counting and cell recovery
This involves count the identification number of bolshie ancestry 
cells per unit of measurement intensity of whole blood, usually by 
automated counting. Red cell recovery may be calculated on the basis 
of the differences in the hematocrit and the volume of the suspension of 
erythrocytes before and after loading. The goal is to minimize the loss 
during the encapsulation subprogram to maximize cell coalescence.
Cell recovery means a number of cells retained after loading. Percent 
cell recovery was determined by counting the number of intact cells per 
cubic mm of packed erythrocytes before and after loading the drug.
%  cell recovery=
Number of cells before loading
-Numberof cells after loading
Numberof cells before loading
×100
Morphological studies
JEOL JSM-6390 LA scanning electron microscope (Jeol Ltd., Tokyo, 
Nippon) prepared with a digital camera, at 20 kV speeding up voltage 
was used to (figure out the worth, amount, or quality of) the (related 
to shape and structure) differences between (usual/commonly and 
regular/healthy) and metformin loaded erythrocytes. After the samples 
were fixed in buffered glutaraldehyde, the aldehyde medium was 
drained off. The cells were rinsed 3 times for 5 minutes in phosphate 
buffer and after fixed in osmium tetroxide for 1 hr. The samples were 
then rinsed with produced/showed water and (having no water or 
not enough water) using a graded ethanol series: 25, 50, 75, 100, and 
another 100%, each for 10 minutes. The samples were rinsed in water, 
removed, mounted on studs, sputter-coated with gold, and then viewed 
using scanning electron micrograph (SEM) [16].
Determination of phospholipid asymmetry
Phospholipid asymmetry of loaded and unloaded erythrocytes was 
studied by Annexin V binding assay using flow cytometer. 20 µl of RBC 
Table 3: Post-hoc Tukey HSD test
Critical values for the Tukey HSD test
Parameters HSD (0.05) HSD (0.01)
Rows (2) 54.98 75.65
Columns (4) 105.1 134.48
Cells (8) 179.83 222.98
Fig. 1: Fourier transform infrared of metformin
Fig. 2: Fourier transform infrared of red blood cell
Fig. 3: Fourier transform infrared of red blood cell-metformin
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suspension was taken. Annexin V binding buffer was added to it, and 
then it is fluorescently labeled with fluorescein isothiocyanate and 
incubated for 15 minutes at the dark condition and detect the presence 
of PS exposed cell.
Mean corpuscular volume (MCV)
MCV is the average volume of red cells in a specimen. Both loaded and 
normal erythrocytes were made to 50% hemocrit. For making 50% 
hemocrit 0.5 ml of packed volume cell of both loaded and normal 
erythrocytes were made to 1 ml using normal saline.
MCV=





No prescribed guidelines are there for the determination of stability 
of resealed erythrocytes. According to published articles, the resealed 
erythrocytes have to be stored in lyophilized form. Hence, the prepared 
resealed erythrocyte formulation was lyophilized. Lyophilized 
product stability was assessed by determining the % hemolysis after 
re-suspending the product [17].
RESULTS AND DISCUSSION
Physical interaction of RBC with metformin
The physical interaction of metformin with RBC and metformin with 
hemoglobin was studied. Physical interaction of metformin with RBC 
was studied by taking FTIR spectra of metformin, lyophilized RBC and 
physical mixture of lyophilized RBC and metformin kept for 7 days. 
The physical interaction of metformin with hemoglobin was studied by 
docking metformin with human oxy hemoglobin chain A.
FTIR of metformin
FTIR of metformin showed a strong absorption band at 1672 and 1512 
is due to C=N stretching vibration. A very weak band in the region 
of 1220-1020 indicates the presence of aliphatic amine. The band 
between the regions of 3400 and 3100 is due to N-H symmetric and 
asymmetric stretching vibration. The very weak intensity band at 910-
660 is due to N-H Wagging. In addition, the presence of methyl group is 
Fig. 4: Docking study result between metformin and hemoglobin
Fig. 5: The amount encapsulated in erythrocyte at 4 different 
concentrations of metformin by the method of endocytosis
Fig. 6: The encapsulation efficiency at four different 
concentration by the method of endocytosis
Fig. 7: Comparison of encapsulation efficiency of metformin 
loaded by endocytosis method with normal transportive 
mechanism at 4 different concentration. Data are expressed as 
mean±standard deviation, 3 samples in each group n=3. 2×4. 
Two-way factorial analysis of variances was carried out followed 
by post hoc Tukey HSD test. p<0.0001 suggests that method of 
endocytosis had significant role in metformin loading
Fig. 8: Percentage cumulative drug release of F0 formulation 
against time. It take 312 hrs (12 days) to release 98.33% of drug. 
Data are expressed as mean±standard deviation, 3 samples in 
each group n=3
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confirmed by the weak intensity band at 2800 range. FTIR of Metformin 
is shown in Fig. 1.
N-H stretching vibrations
The N-H stretching vibrations are found in the region 3550-3250 cm−1. 
In this study, medium to strong intensity band appearing at 3425 cm−1 
is assigned to N-H stretching vibration. The band appearing at 3176 
and 3300 cm−1 are of medium intensity in nature and have been assigned 
as symmetric and asymmetric N-H stretching vibrations, respectively.
N-H deformation vibrations
The N-H deformation vibrations occur in the region of 1650-1581 cm−1. 
In the present spectra, strong absorption occurs at 1672, 1602, 1512 
frequencies.
C-N stretching
The C-N stretching vibrations generally occur in the region 
1170-1040 cm−1. In this study, the weak and medium to weak intensity 
bands appearing at frequencies 1170, 1097 and 1033 cm−1 in IR 
spectrum.
N-H2 rocking vibrations and N-H wagging
In metformin hydrochloride, a weak band at 800 cm−1 have been 
assigned to N-H2 rocking vibrations. N-H wagging vibrations appear at 
the region 910-660.
FTIR of RBC
FTIR of RBC shows a broad peak in 3000-3600 range is peculiar for OH 
stretching of the group present in phospholipid sphingomyelin in the 
outer layer of RBC. One weak band just below 3000 is attributed due 
to CH stretching vibration. The peak at 1678 is due to Amide I shift and 
weak peak below 1500 is due to Amides II and III shift. Symmetric and 
asymmetric stretching vibrations from the phosphate group are seen 
in the FTIR spectra in the region of 950-1250 cm−1. FTIR of RBC was 
shown in Fig. 2.
FTIR of physical mixture of lyophilized RBC and metformin
Prominent Peaks present in metformin is also present in RBC. Hence, 
when the FTIR spectra were taken for metformin-RBC complex, the 
addition of peaks occur due to Fermi resonance. The broad peak at 
3344 may be due to the interaction of N-H2 group with the hydrophilic 
domain of cell membrane. This is advantageous for the process of 
endocytosis. For the process of endocytosis to be occurring, the drug 
molecule should possess a group that binds with the hydrophilic 
domain of the membrane. Only after binding with the hydrophilic 
domain the process of endocytosis takes place. FTIR of RBC-Metformin 
was shown in Fig. 3.
Physical interaction of metformin with hemoglobin
The docking study reveals the presence of hydrogen bonding between 
the drug and amino acids ASP126 and LYS127. The binding score 
was −3.33, and the absence of other interactions like cation-cation 
interaction, or pi cation interaction suggests only a weak interaction 
was there between metformin and hemoglobin. Docking results of 
Metformin with Hemoglobin was shown in Fig. 4.
Characterization of metformin loaded resealed erythrocytes
Encapsulation efficiency
The encapsulation of metformin in erythrocytes was done by the 
method of endocytosis and by normal transportive mechanism. The 
encapsulation efficiency was calculated for erythrocyte loaded by 
both the method. Concentrations 1, 4, 7, 10 mg/ml of metformin were 
used for encapsulation. The amount encapsulated in erythrocytes at 4 
different concentrations of Metformin is showed in Fig. 5.
From the graph, it was evident that when concentration 10 mg/ml was 
used the amount of metformin encapsulated is greater.
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The corresponding encapsulation efficiency of different concentration 
of metformin was calculated. The encapsulation efficiency at four 
different concentration of Metformin was shown in Fig. 6.
The encapsulation efficiency was calculated for erythrocytes loaded 
by endocytosis and was compared with drug loaded by normal 
transportive mechanism. In normal transportive mechanism, 
the drug loading was carried out in PBS alone. To determine 
encapsulation efficiency, the RBC membrane was deproteinized 
using methanol followed by centrifugation. 1 ml of the supernatant 
was pipetted out, and drug content was determined using UV-visible 
spectrophotometer at 232 nm and encapsulation efficiency was 
determined. Comparison of encapsulation efficiency of metformin 
loaded by endocytosis method with normal transportive mechanism 
at 4 different concentration is shown in Fig. 7.
To check whether endocytosis has any significant role in metformin 
loading 2×4 two-way factorial analysis of variance (ANOVA) was 
performed. In two-way ANOVA main effect and interaction effect can 
be calculated. By comparing the method of endocytosis with normal 
transportive mechanism, it was revealed that the mechanism of drug 
loading depend not only on endocytosis, some amount of encapsulation 
occur due to the effect of diffusion also.
The encapsulation efficiency may depend on two factors methods 
of drug loading and concentration. Thus it has 8 treatment groups. 
(First factor have 2 level, while second factor have 4 level; 2×4=8). The 
degree of freedom (DF) for the type of method is 2−1=1 and DF for 
concentration is 4−1=3. There are 1×3=3 degrees of freedom for the 
interaction between the type of method and concentration.
The HSD test between row means can be meaningfully performed only if 
the row effect is significant; between column means, only if the column 
effect is significant; and between cell means, only if the interaction 
effect is significant. Thus, it is relevant that method of endocytosis has 
any significant role in metformin loading.
In normal transportive mechanism, drug enters into the erythrocytes 
by simple diffusion. The metformin loaded into erythrocytes by the 
mechanism of diffusion will bind with hemoglobin by forming hydrogen 
bond (Met---Hb). Metformin loaded into erythrocyte by the process of 
endocytosis will reside inside the endocytic vacuoles.
In vitro drug release
The drug release study for the concentration with highest loading 
efficiency was carried out and is given below. 10 mg/ml concentration 
loaded by the method of endocytosis was having highest loading 
efficiency and it was used for in vitro drug release study. To further 
retard the release rate crosslinker was added. Glutaraldehyde was 
used here as the cross-linking agent, as it makes more chemically and 
thermostable cross-links with protein than other aldehyde crosslinkers. 
Glutaraldehyde of concentrations 0.2%, 0.4%, 0.6%and 0.8% v/v 
were added to F0 formulation to get F1, F2, F3 and F4 formulations, 
respectively. Percentage cumulative drug release of F0 Formulation was 
shown in Fig. 8.
Effect of cross-linking agent in drug release
In vitro release of metformin was also taken for glutaraldehyde 
treated formulation in order to study the effect of concentration of 
glutaraldehyde on release rate. It was found that as the concentration 
of cross-linking agent increases release rate found to be decreased. The 
release data were taken only for 12 days because the in vitro stability 
of resealed erythrocyte formulation at 37°C is less. The percentage cell 
recovered after 12 days were decreasing to a significant extent and also 
the formulation is susceptible to contamination. From the graph, it was 
found that as the concentration of glutaraldehyde increases the release 
rate found to be decreased. To check the statistical significance of 
release rate retardation One-way ANOVAs test followed by bonferonni 
multiple comparison test was carried out and suggest the concentration 
of glutaraldehyde have a significant role in release retardation. The 
post hoc test bonferronni multiple comparison tests was meaningfully 
performed only when there was a significant difference in release rate 
of formulations at 95% confidence interval.
Kinetic modeling of release rate
Like any vesicular bodies, erythrocyte is made up of phospholipid 
bilayer. Kinetic model is applied to predict the release pattern from 
loaded erythrocytes in vitro. 98.34% of drug is released within 
12 days from F0 formulation. Therefore, the kinetic model is applied 
to glutaraldehyde untreated F0 formulation as we can predict model 
after almost all encapsulate drug is release. Kinetic data modelling for 
F0 formulation is shown in Fig. 9.
R2 value of zero order kinetics was greater compared to first order 
kinetics. Hence, the best fit graph is the zero order kinetic graph. In vitro 
release of metformin from loaded erythrocytes follows zero order 
kinetics. To confirm this and predict the mechanism of release Higuchi 
plot and Korsmeyer-Peppas model was constructed. The n value of 
Korsmeyer-Peppas graph was >0.5 suggests non-Fickian diffusion, 
i.e., dissolution followed by diffusion. The initial retardation in release 
rate might be due to the weak interaction between metformin and 
hemoglobin (the docking energy of −3.33), the hydrogen bonding 
between the drug and amino acids ASP126 and LYS127. Hence, the 
breaking of this hydrogen bond is required for the release of metformin 
from erythrocyte. Further release occurs from endocytic vesicles.
Several hematological parameters were also assessed for loaded and 
unloaded erythrocyte to predict any significant difference between 
loaded and unloaded cell.
Osmotic fragility
It is a test that measures the resistance to blood destruction of red 
platelets (RBC) presented to hypotonic solutions. RBC are presented 
to a progression of salt water (NaCl) solutions with increasing 
dilution. The prior blood destruction happens, the more prominent 
is osmotic easily-broken quality of RBC. RBC burst in hypotonic 
(<0.9% NaCl), and shrink (crenate) in hypertonic solutions (>0.9% 
NaCl). In hypotonic medium a membrane break happens, allowing 
(a part of the blood that carries oxygen) (Hb) to exit from the cells. By 
measuring Hb concentration, the % of blood destruction at different 
NaCl concentrations can be calculated. Normally hemolysis onset at 
0.45-0.5% NaCl and complete at: 0.3-0.33% NaCl. Osmotic fragility 
is affected by cell membrane permeability and surface-to-volume 
ratio. This test of resealed erythrocytes is an indicator of the possible 
changes in cell membrane (honest and good human quality/wholeness 
or completeness) and the resistance of these cells to osmotic pressure 
of the suspension medium. Osmotic fragility test gives an idea about 
the fragility of erythrocytes with respect to the change in tonicity of 
the surrounding of erythrocytes. Osmotic fragility of both loaded and 
normal erythrocytes are calculated and are given in Fig. 10. The loaded 
erythrocyte has greater osmotic fragility than the unloaded one. Paired 
t-test is found, and the value suggests that the difference in osmotic 
fragility of both loaded and unloaded is not statistically significant. The 
osmotic fragility test of normal and loaded red blood cell is given in 
Fig. 10.
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Turbulence shock studies/turbulence fragility studies
The disturbance easily-broken quality is one more (typical and expected) 
feature of erythrocytes that depends upon changes in the (honest and 
good human quality/wholeness or completeness) of cellular membrane 
and reflects resistance of loaded cells against blood destruction resulting 
from (full of violently swirling disorder) flow within circulation. 
Turbulence test provides the idea about the shock that is supposed to 
be affected to erythrocytes when it passes through small capillaries of 
human body. The turbulence shock was calculated for both loaded and 
unloaded erythrocytes and the significant difference between the loaded 
and normal erythrocytes and paired t-test value suggested even though 
the turbulence shock is greater for loaded erythrocytes, the difference 
is not considered to be statistically significant. The turbulance shock 
studies of normal and loaded red blood cells is given in Fig. 11.
Cell counting and cell recovery
% cell recovered was calculated and was found to be 73-78%, which 
suggests that the loading technique was less destructive.
Morphological studies
To find out the morphological difference of erythrocyte after loading 
of metformin by endcytosis method, the SEM image of both loaded 
and normal was taken using JEOL JSM-6390 LA scanning electron 
microscope. The some echinocytes transition was seen even in normal 
RBC which might be due to storage lesion. But the echinocyte was 
significantly less in number compared to discocytes. The SEM image of 
normal RBC is given in Fig. 12.
Even after loading metformin also, there was no significant shape 
transformation had occurred. SEM study result suggests that biconcave 
shape of RBC is retained even after loading. This suggests that loading 
metformin by the process of endocytosis was a less destructive 
technique.
Determination of phospholipid asymmetry
Maintenance of phospholipid asymmetry of erythrocyte was checked 
using in order to determine whether the loading process or the 
drug metformin had any role in disturbing the lipid asymmetry of 
erythrocyte. Like, any other cells, erythrocyte is also composed 
of phospholipid bilayer. The outer layer of it is uncharged while 
inner layer is charged. The former is composed of PC (30%) and 
SM (25%) while latter is composed of lipids like phosphatidyl 
ethanolamine (28%) and PS (14%). Between the lipoid bilayer is 
the cholesterol. These phospholipids are non randomly arranged 
in bilayer in normal cells. Hence the name lipid asymmetry. 
Phospholipid asymmetry is maintained throughout the lifespan of 
the cell. Once the cell enters into apoptosis stage, this phospholipid 
asymmetry gets distorted. When lipid asymmetry is distorted, 
amine containing phospholipids (PS) will expose, PS act as a self-
marker for macrophages and removed from the body by engulfing 
them. Erythrocytes can be used as drug carrier for slow release 
depot formulation provided that there should not any exposure of 
PS during the loading procedure. Exposure of PS would lead to rapid 
recognition of erythrocytes by mononuclear phagocytic system. 
Detection of phospholipid asymmetry is studied by binding with 
fluorescently labeled Annexin V. Annexin V is a 35-36 kDa Ca2+ 
dependent phospholipid-binding protein that has a high affinity for 
PS, and binds to cells with exposed PS.
Quadrant 3 (Q3): This quadrant shows the no: Of cells that do not have 
affinity for Annexin, which means all cells are live and no exposure of PS.
Quadrant 4 (Q4): Annexin V positive cell is quantified in this table. 
That means it gives information about the apoptotic cell or PS exposed 
erythrocytes.
Q1 and Q2 have no role in determining the phospholipid asymmetry 
of RBC as these quadrants are meant for nucleus-containing cells. This 
quadrants give positive results for propidium iodide dye which stains 
the nucleus. From the four quadrant table, it was observed that there 
was significantly less amount of cells in Q4 region for both loaded and 
normal erythrocyte. Hence it revealed that the loading of metformin 
in erythrocytes by the method of Endocytosis was a less destructive 
technique. The numbers of exposed PS cells were significantly less. 
Fig. 10: The osmotic fragility test of normal and loaded red 
blood cell. % hemolysis is ploted against concentration of 
sodium chloride. Data are expressed as mean±standard 
deviation, 3 samples in each group n=3
Fig. 11: The turbulence shock studies of normal and loaded 
red blood cell. % hemolysis is ploted against number of passes 
through a syringe at a rate of 10 ml/minutes. Data are expressed 
as mean±standard deviation, 3 samples in each group n=3
Fig. 12: Scanning electron micrograph image of normal 
erythrocytes
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Hence, the drug loaded erythrocyte would remain in the circulation 
without recognized by the mononuclear phagocytic system. That means 
the metformin loaded erythrocyte would remain in the circulation 
exactly the same life span of normal RBC.
MCV
The mean cell quantity points to shows the volume of the “average” 
red cell in a sample. MCV is higher or decreased (going along with) 
average red cell size; i.e., low MCV points to/shows microcytic (small 
average RBC size), (usual/commonly and regular/healthy) MCV 
points to normocytic ((usual average RBC size), and high MCV points 
to macrocytic (large average RBC size). The reference range for MCV 
is 80-96 fL/red cell in adult. The unloaded erythrocyte shows an MCV 
value of 93 fl and metformin loaded erythrocytes shows an MCV value 
of 95 fl indicates a normal average RBC size even after loading.
Stability studies
There is no prescribed stability studies guideline for resealed 
erythrocyte formulation. According to literature survey, resealed 
erythrocytes are lyophilized after loading and stored at 4°C. However, 
the SEM image of lyophilized product results in the distortion of RBC 
shape. Researchers are going on in the field of freeze-drying of blood 
product; yet no successful outcome was reported.
From the table, it was revealed that for F0 formulation that is 
formulation with no glutaraldehyde cross-linking was stable only for 
28 days at 4°C in erythrosol solution.
CONCLUSION
This study aimed to retard the release of metformin by encapsulating 
in carrier erythrocyte. The encapsulation was done by the method of 
endocytosis so that the metformin would reside inside the endocytic 
vacuoles. Hence, the release might be retarded for the metformin which 
was having a very small molecular weight. In addition, from the study, 
it was revealed that some amount of metformin encapsulated by the 
mechanism of diffusion also. Metformin had hydrogen bonding with 
hemoglobin as suggested by docking study. Both endocytosis and 
diffusion take place in drug loading mechanism. The loaded cells were 
then characterized in vitro for osmotic fragility, drug release, resistance 
to turbulence shock, mean corpuscular volume, and maintenance of 
phospholipid asymmetry. The cells showed higher osmotic easily-
broken quality and lower resistance to disturbance shock as compared 
to the healthy cells. It was found about 98.34% of metformin release for 
about 12 days. A near zero order release kinetics was observed from 
metformin loaded erythrocytes and glutaraldehyde treatment of loaded 
cells resulted in further drug release retardation. Lipid asymmetry 
of erythrocyte was maintained even after loading metformin which 
suggests the metformin loaded erythrocyte would remain in the 
circulation with exactly the same half-life of normal erythrocyte. The 
near zero order release kinetics, comparable hematological indices 
with normal erythrocytes and maintenance of lipid asymmetry 
of erythrocytes makes them a perfect carrier for parenteral slow 
release depot formulation of metformin. The loaded erythrocyte has 
all hematological and another parameter almost similar to normal 
erythrocytes; so would remain in the circulation with almost the same 
half-life of normal erythrocyte and the retardation in metformin release 
would decrease the dosing frequency. Even though the stability was less 
for resealed erythrocyte formulation, it would act as a perfect carrier 
for metformin for retarding the release.
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